New hope for kidney cancer patients whose disease returns after standard therapy
Disease control
Recruiting now
This study tests a new drug called zanzalintinib, either alone or with an immunotherapy (nivolumab), in people with advanced kidney cancer that got worse after standard adjuvant therapy. About 70 adults will take part. The goal is to see if the drug shrinks tumors and is safe.
Phase: PHASE2 • Sponsor: Karie Runcie • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC